XNAS · Healthcare · Biotechnology
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-05 | Q1 2026 | -2.52 | -2.28 | +9.52% | $138.0M | ✅ Beat | -0.25% | -1.93% | — |
| 2026-03-10 | Q4 2025 | -0.47 | -0.38 | +19.15% | $1.06B | ✅ Beat | +1.60% | +13.08% | +9.64% |
| 2025-11-03 |
| Q3 2025 |
| 0.75 |
| -0.14 |
| -118.67% |
| $1.78B |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-04 | Q2 2025 | -1.31 | -1.82 | -38.93% | $295.7M | ❌ Miss | — | — | — |
| 2025-05-05 | Q1 2025 | -2.35 | -1.82 | +22.55% | $192.2M | ✅ Beat | — | — | — |
| 2025-03-10 | Q4 2024 | 0.37 | 1.15 | +210.81% | $1.27B | ✅ Beat | — | — | — |
| 2024-11-04 | Q3 2024 | -1.67 | 0.89 | +153.29% | $1.37B | ✅ Beat | — | — | — |
| 2024-08-05 | Q2 2024 | -2.20 | -3.62 | -64.55% | $138.6M | ❌ Miss | — | — | — |
Showing last 8 quarters.